[en] The aim of this study was to assess the usefulness of fluorine-18 tluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) in the post-therapy surveillance of endometrial carcinomas. Forty-one fully corrected whole-body PET studies were performed in 34 women with previously treated endometrial cancers as a part of their follow-up programme. In 28 studies, FDG PET was indicated to localise a recurrence suspected at the control visits on the basis of clinical examination and/or radiological abnormalities (chest X-ray, CT or MRI) and/or elevated tumour marker levels (CA125, CEA). Another 13 studies were performed as a simple surveillance procedure. Overall, in 26 studies PET detected recurrent disease, which was confirmed either by histology (n=7) or by clinical and radiological outcomes (n=19). In 88% of the cases, the PET findings confirmed recurrence suggested by routine follow-up. In the remaining 12% of cases, PET detected asymptomatic recurrences that were unsuspected at the control visits. Whole-body PET accurately localised the site of confirmed recurrences as being above and below the diaphragm in 50%, only below the diaphragm in 35% and only above the diaphragm in 15%. In one patient, however, PET missed microscopic lung metastases shown on thoracic CT, and in three studies, metabolic imaging results were not confirmed. In I I of 12 negative PET studies, no subsequent clinical or radiological recurrences were observed with a median follow-up of 10 months. Overall, the results of PET agreed well with the final diagnosis (Cohen's kappa coefficient =0.78). In 9/26 patients (35%) with confirmed recurrences, the PET findings significantly altered the treatment choice by detecting either clinically or radiologically unsuspected distant metastases. The sensitivity, specificity, diagnostic accuracy and positive and negative predictive values of FDG PET imaging in the post-therapy surveillance of endometrial carcinomas were 96%, 78%, 90%, 89% and 91 %, respectively. Indeed, the high likelihood ratio for a positive test result (4.5) and the low likelihood ratio for a negative test result (0.05) demonstrated the clinical utility of metabolic imaging in "ruling in" disease as well as "ruling out" recurrence. In conclusion, whole-body FDG PET appears useful in the post-therapy surveillance of endometrial cancers, both for the accurate localisation of suspected recurrences and for the detection of asymptomatic recurrent disease.
Disciplines :
Radiology, nuclear medicine & imaging Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Belhocine, Tarik
De Barsy, Caroline
Hustinx, Roland ; Université de Liège - ULiège > Département des sciences cliniques > Médecine nucléaire
Willems-Foidart, Jacqueline
Language :
English
Title :
Usefulness of F-18-FDG PET in the post-therapy surveillance of endometrial carcinoma
Publication date :
September 2002
Journal title :
European Journal of Nuclear Medicine and Molecular Imaging
Salvesen H.B. (2001) Routine follow up after treatment for gynecological cancer. Tidsskr Nor Laegeforen 121:1253-1265.
Pazdur R., Coia L.R., Hoskins W.J., Wagman L.D. Cancer management: a multidisciplinary approach, 5th edn., New York: PRR; 2001.
Benedet J.L., Bender H., Jones H. III, Ngan H.Y., Pecorelli S. (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet , FIGO Committee on Gynecologic Oncology; 70:209-262.
Salvesen H.B., Akslen L.A., Iversen T., Iversen O.E. (1997) Recurrence of endometrial carcinoma and the value of routine follow up. Br J Obstet Gynaecol 104:1302-1307.
Shumsky A.G., Stuart G.C., Brasher P.M. (1994) An evaluation of routine follow-up of patients treated for endometrial carcinoma. Gynecol Oncol 55:229-233.
Owen P., Duncan I.D. (1996) Is there any value in the long term follow up of women treated for endometrial cancer?. Br J Obstet Gynaecol 103:710-713.
Ebner F., Kressel H.Y., Mintz M.C. (1988) Tumor recurrence versus fibrosis in the female pelvis: Differentiation with MR imaging at 1.5 T. Radiology 166:333-340.
Kinkel K., Ariche M., Tardivon A.A. (1997) Differentiation between recurrent tumor and benign conditions after treatment of gynecologic pelvic carcinoma: Value of dynamic contrast- enhanced subtraction MR imaging. Radiology 204:55-63.
Siegelman E.S., Outwater E.K. (1999) Tissue characterization in the female pelvis by means of MR imaging. Radiology 212:5-18.
Sovik E., Lien H.H., Tveit K.M. (1993) Postirradiation changes in the pelvic wall. Findings on MR. Acta Radiol 34:573-576.
Connor J.P., Andrews J.I., Anderson B., Buller R.E. (2000) Computed tomography in endometrial carcinoma. Obstet Gynecol 95:692-696.
Cherchi P.L., Dessole S., Ruiu G.A. (1999) The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma. Eur J Gynaecol Oncol 20:315-317.
Kurihara T., Mizunuma H., Obara M. (1998) Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma. Gynecol Oncol 69:192-196.
Wylie J., Irwin C., Pintilie M. (2000) Results of radical radiotherapy for recurrent endometrial cancer. Gynecol Oncol 77:66-72.
Morris M., Alvarez R.D., Kinney W.K., Wilson T.O. (1996) Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol 60:288-291.
Dimopoulos M.A., Papadimitriou C.A., Georgoulias V. (2000) Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: Long-term results of a phase II multicenter study. Gynecol Oncol 78:52-57.
Thigpen T., Brady M., Alvarez R. (1999) Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose response study by the Gynecologic Oncology Group. J Clin Oncol 17:1736-1744.
Delbeke D. (1999) Oncological applications of FDG PET imaging. J Nucl Med 40:1706-1715.
Delbeke D. (1999) Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med 40:591-603.
Eubank W.B., Mankoff D.A., Vesselle H.J. (2002) Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 22:5-17.
Lonneux M., Borbath I.I., Berliere M., Kirkove C., Pauwels S. (2000) The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging 3:45-49.
Zimny M., Siggelkow W., Schroder W. (2001) 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 83:310-315.
Jimenez-Bonilla J., Maldonado A., Morales S. (2000) Clinical impact of 18F-FDG-PET in the suspicion of recurrent ovarian carcinoma based on elevated tumor marker serum levels. Clin Positron Imaging 3:231-236.
Sun S.S., Chen T.C., Yen R.F. (2000) Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer. Anticancer Res 21:2957-2961.
Grigsby P.W., Dehdashti F., Siegel B.A. (1999) FDG-PET evaluation of carcinoma of the cervix. Clin Positron Imaging 2:105-109.
Umesaki N., Tanaka T., Miyama M. (2000) The role of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET) in the diagnosis of recurrence and lymph node metastasis of cervical cancer. Oncol Rep 7:1261-1264.
Kubota K. (2001) From tumor biology to clinical Pet: A review of positron emission tomography (PET) in oncology. Ann Nucl Med 15:471-486.
Czernin J., Phelps M.E. (2002) Positron emission tomography scanning: Current and future applications. Annu Rev Med 53:89-112.
Lapela M., Leskinen-Kallio S., Varpula M. (1994) Imaging of uterine carcinoma by carbon-11-methionine and PET. J Nucl Med 35:1618-1623.
Nakahara T., Fujii H., Ide M. (2001) F-18 FDG uptake in endometrial cancer. Clin Nucl Med 26:82-84.
Grigsby P.W., Dehdashti F., Siegel B.A. (1999) FDG-PET evaluation of recurrent endometrial carcinoma. 7th Biennial Meeting of the International Gynecologic Cancer Society, Rome, Italy, 26-30 September; .
Spellman C.M., Fottrell P.F., Baynes S. (1973) A study of some enzymes and isoenzymes of carbohydrate metabolism in human endometrium during the menstrual cycle. Clin Chim Acta 48:259-268.
Pepe G.J., Yochim J.M. (1971) Glucose-6-phosphate dehydrogenase activity in the endometrium and myometrium of the rat uterus during the estrous cycle and progestation. Biol Reprod 5:161-171.
Singhal R.L., Valadares J.R. (1970) Estrogenic regulation of uterine pyruvate kinase. Am J Physiol 218:321-327.
Rose P.G. (1996) Endometrial carcinoma. N Engl J Med 335:640-649.
Hubner K.F., McDonald T.W., Niethammer J.G. (1993) Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-(F18) deoxyglucose. Gynecol Oncol 51:197-204.
Shreve P.D., Anzai Y., Wahl R.L. (1999) Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants. Radiographics 19:61-77.
Holder W.D. Jr., White R.L., Zuger J.H., Easton E.J. Jr., Greene F.L. (1998) Effectiveness of positron tomography for the detection of melanoma metastases. Ann Surg 227:764-765.
Nakamoto Y., Eisbruch A., Achtyes E.D. (2002) Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy. Gynecol Oncol 84:289-295.
Rose P.G., Sommers R.M., Reale F.R. (1994) Serial serum CA 125 measurements for evaluation recurrence in patients with endometrial carcinoma. Obstet Gynecol 177:231-236.
Charron M., Beyer T., Bohnen N.N., Kinahan P.E., Dachille M., Jerin J., Nutt R., Meltzer C.C., Villemagne V., Townsend D.W. (2000) Image analysis in patients with cancer studied with a combined PET and CT scanner. Clin Nucl Med 25:905-910.
Makhija S., Howden N., Edwards R., Kelley J., Townsend D.W., Meltzer C.C. (2002) Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: A retrospective review. Gynecol Oncol 85:53-58.
Beggs A.D., Hain S.F., Curran K.M., O'Doherty M.J. (2002) FDG-PET as "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med 29:542-546.
Hart K.B., Han I., Shamsa F. (1998) Radiation therapy for endometrial cancer in patients treated for postoperative recurrence. Int J Radiat Oncol Biol Phys 41:7-11.
Podczaski E., Kaminski P., Gurski K. (1992) Detection and patterns of treatment failure in 300 consecutive cases of "early" endometrial cancer after primary surgery. Gynecol Oncol 47:323-327.